Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 1
2008 1
2016 1
2019 4
2020 1
2021 2
2022 3
2023 5
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Management of Rectal Cancer.
Schlechter BL. Schlechter BL. Hematol Oncol Clin North Am. 2022 Jun;36(3):521-537. doi: 10.1016/j.hoc.2022.03.002. Epub 2022 May 13. Hematol Oncol Clin North Am. 2022. PMID: 35577705 Review.
Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer.
Singh H, Keller RB, Kapner KS, Dilly J, Raghavan S, Yuan C, Cohen EF, Tolstorukov M, Andrews E, Brais LK, da Silva A, Perez K, Rubinson DA, Surana R, Giannakis M, Ng K, Clancy TE, Yurgelun MB, Schlechter BL, Clark JW, Shapiro GI, Rosenthal MH, Hornick JL, Nardi V, Li YY, Gupta H, Cherniack AD, Meyerson M, Cleary JM, Nowak JA, Wolpin BM, Aguirre AJ. Singh H, et al. Among authors: schlechter bl. Clin Cancer Res. 2023 Nov 14;29(22):4627-4643. doi: 10.1158/1078-0432.CCR-22-3930. Clin Cancer Res. 2023. PMID: 37463056 Free PMC article.
Genes and Race in Colon Cancer.
Stebbing J, Schlechter BL. Stebbing J, et al. Among authors: schlechter bl. J Clin Oncol. 2024 Feb 1;42(4):369-372. doi: 10.1200/JCO.23.02094. Epub 2023 Dec 7. J Clin Oncol. 2024. PMID: 38060992 No abstract available.
A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.
Huffman BM, Feng H, Parmar K, Wang J, Kapner KS, Kochupurakkal B, Martignetti DB, Sadatrezaei G, Abrams TA, Biller LH, Giannakis M, Ng K, Patel AK, Perez KJ, Singh H, Rubinson DA, Schlechter BL, Andrews E, Hannigan AM, Dunwell S, Getchell Z, Raghavan S, Wolpin BM, Fortier C, D'Andrea AD, Aguirre AJ, Shapiro GI, Cleary JM. Huffman BM, et al. Among authors: schlechter bl. Clin Cancer Res. 2023 Dec 15;29(24):5047-5056. doi: 10.1158/1078-0432.CCR-23-2005. Clin Cancer Res. 2023. PMID: 37819936
CCR5 and CCL5 in metastatic colorectal cancer.
Schlechter BL, Stebbing J. Schlechter BL, et al. J Immunother Cancer. 2024 May 7;12(5):e008722. doi: 10.1136/jitc-2023-008722. J Immunother Cancer. 2024. PMID: 38719543 Free PMC article.
Highly Sensitive Circulating Tumor DNA Assay Aids Clinical Management of Radiographically Occult Isolated Peritoneal Metastases in Patients With GI Cancer.
Singh H, Klempner SJ, Melnitchouk N, Chander DP, Negrea OG, Patel AK, Schlechter BL, Rubinson DA, Huffman BM, Nambiar C, Remland J, Andrews E, Leahy ME, Brais LK, Enzinger PC, Mamon HJ, Giannakis M, Meyerhardt JA, Ng K, Perez KJ, Aguirre AJ, Clark JW, Cleary JM, Wolpin BM. Singh H, et al. Among authors: schlechter bl. JCO Precis Oncol. 2023 Jun;7:e2200572. doi: 10.1200/PO.22.00572. JCO Precis Oncol. 2023. PMID: 37343200
Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial.
Huffman BM, Basu Mallick A, Horick NK, Wang-Gillam A, Hosein PJ, Morse MA, Beg MS, Murphy JE, Mavroukakis S, Zaki A, Schlechter BL, Sanoff H, Manz C, Wolpin BM, Arlen P, Lacy J, Cleary JM. Huffman BM, et al. Among authors: schlechter bl. JAMA Netw Open. 2023 Jan 3;6(1):e2249720. doi: 10.1001/jamanetworkopen.2022.49720. JAMA Netw Open. 2023. PMID: 36602796 Free PMC article. Clinical Trial.
RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer.
Singh H, Sahgal P, Kapner K, Corsello SM, Gupta H, Gujrathi R, Li YY, Cherniack AD, El Alam R, Kerfoot J, Andrews E, Lee A, Nambiar C, Hannigan AM, Remland J, Brais L, Leahy ME, Rubinson DA, Schlechter BL, Meyerson M, Kuang Y, Paweletz CP, Lee JK, Quintanilha JCF, Aguirre AJ, Perez KJ, Huffman BM, Rossi H, Abrams TA, Kabraji S, Trusolino L, Bertotti A, Sicinska ET, Parikh AR, Wolpin BM, Schrock AB, Giannakis M, Ng K, Meyerhardt JA, Hornick JL, Sethi NS, Cleary JM. Singh H, et al. Among authors: schlechter bl. Clin Cancer Res. 2024 Apr 15;30(8):1669-1684. doi: 10.1158/1078-0432.CCR-23-2581. Clin Cancer Res. 2024. PMID: 38345769
23 results